Sermorelin acetate is the acetate salt of sermorelin, a synthetic 29-amino-acid peptide corresponding to the N-terminal fragment of human growth hormone-releasing hormone, designated GRF(1-29)-NH2 in the literature. AminoOptimization Group supplies it as a lyophilised research powder in a 5 mg presentation, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is Sermorelin Acetate?
Sermorelin reproduces the first 29 residues of endogenous growth hormone-releasing hormone, GHRH(1-44), with the C-terminal residue amidated. Published receptor-binding work identifies this truncated fragment as retaining activity comparable to the full 44-residue hormone at the GHRH receptor, which is why GRF(1-29) rather than the complete sequence became the standard reference fragment in GHRH pharmacology. The acetate designation refers to the counter-ion used in the salt form of the peptide, a common presentation for lyophilised research peptides intended to stabilise the powder and support consistent reconstitution behaviour relative to the free base.
What distinguishes sermorelin from related GHRH-fragment analogues is that it carries the native amino acid sequence across its full length, with no substitutions introduced. This includes the N-terminal motif that dipeptidyl peptidase-4 (DPP-4) recognises as a cleavage site. Modified analogues such as CJC-1295 (No DAC) were engineered specifically to replace residues at and near this site to resist that cleavage; sermorelin was not, and the literature treats it as the unmodified reference point against which such stabilised analogues are compared. Tesamorelin, built on the longer GRF(1-44) backbone with its own N-terminal modification, is a separate line of GHRH-analogue design and is not structurally interchangeable with sermorelin.
Because the native sequence is retained, sermorelin is described in enzymatic degradation studies as susceptible to rapid proteolytic cleavage, principally by DPP-4 and other serum peptidases. This is a defined chemical property of the unmodified sequence, and it is the reason sermorelin functions in study designs as the comparator for engineered, protease-resistant GHRH analogues.
Specifications
- Compound: Sermorelin Acetate / GRF(1-29)-NH2
- CAS number: 114466-38-5
- Molecular formula: C149H246N44O42S
- Molecular weight: 3357.93 g/mol
- Purity: 99% by HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 5 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
GHRH-fragment analogues as a class are studied for what they reveal about the somatotropic axis: the literature examines how agonism at the GHRH receptor on anterior pituitary somatotrophs is transduced through the cAMP/PKA signalling pathway, and how the kinetics of receptor occupancy relate to downstream signalling output in model systems.
Sermorelin’s specific role in that body of work is as the unmodified reference sequence. Structure-activity relationship studies use it to isolate the effect of individual amino acid substitutions found in stabilised analogues, comparing receptor binding affinity and resistance to enzymatic cleavage against the native fragment. It also appears in degradation-kinetics work examining DPP-4 and related protease activity on GHRH-derived peptides, since its intact cleavage site makes it a useful positive control for that class of assay.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical where a single-use preparation is required.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration depends on how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder, and the unmodified sequence of sermorelin makes solution stability an especially relevant variable to control for in any protocol. Avoid repeated freeze-thaw cycles, a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
What is the difference between sermorelin and CJC-1295?
Both are built on the same 29-residue GHRH fragment. Sermorelin retains the native amino acid sequence throughout, including the site recognised by DPP-4. CJC-1295 substitutes several of those residues specifically to resist that cleavage. Researchers select between them depending on whether their study calls for the native reference sequence or a protease-resistant analogue.
Is Sermorelin Acetate approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
Why is this product supplied as an acetate salt rather than a free base?
Acetate is a common counter-ion for lyophilised peptides. It is used in manufacturing to support powder stability and consistent reconstitution behaviour, and its presence does not change the amino acid sequence of the peptide itself.
How much diluent should be used?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.